Andrew Weinstein, MD, FAAD

home / authors / andrew-weinstein-md-faad

Articles

Expert Perspectives on BOLT clinical trial data

Jonathan S Zager, MD, FACS, FSSO;Lilia Correa-Selm, MD, FAAD, FACMS;Aaron Farberg, MD;John Strasswimmer, MD, PhD;Andrew Weinstein, MD, FAAD

October 5th 2023

John Strasswimmer, MD, PhD comments on the impressive utility of both vismodegib and sonidegib in patients with advanced basal cell carcinoma and Jonathan S Zager, MD, FACS, FSSO provides his insight into the clinical utility of both of these treatments.

Data Review of 2 doses of Sonidegib in Advanced Basal Cell Carcinoma (BOLT Trial)

Jonathan S Zager, MD, FACS, FSSO;Lilia Correa-Selm, MD, FAAD, FACMS;Aaron Farberg, MD;John Strasswimmer, MD, PhD;Andrew Weinstein, MD, FAAD

October 5th 2023

Jonathan S Zager, MD, FACS, FSSO reviews the clinical trial data relating to the BOLT study examining the use of sonidegib treatment in patients with locally advanced basal cell carcinoma, highlighting the critical differences in study design and data readouts between the BOLT and EVRIANCE trials.

Expert Perspectives on EVRIANCE clinical trial data

Jonathan S Zager, MD, FACS, FSSO;Lilia Correa-Selm, MD, FAAD, FACMS;Aaron Farberg, MD;John Strasswimmer, MD, PhD;Andrew Weinstein, MD, FAAD

September 25th 2023

Andrew Weinstein, MD, MPH, FAAD and Jonathan S Zager, MD, FACS, FSSO explore the potential rationale behind observed variations in the and GLI and PTCH expression data within the EVRAINCE trial and comment on potential factors contributing to bias within the study.

Data Review of the Efficacy and Safety of Vismodegib in Advanced Basal Cell Carcinoma (EVRIANCE Trial)

Jonathan S Zager, MD, FACS, FSSO;Lilia Correa-Selm, MD, FAAD, FACMS;Aaron Farberg, MD;John Strasswimmer, MD, PhD;Andrew Weinstein, MD, FAAD

September 25th 2023

Lilia Correa-Selm, MD, FAAD, FACMS, reviews the clinical trial data relating to the EVRIANCE study examining the use of vismodegib treatment in patients with locally advanced basal cell carcinoma, highlighting key efficacy and safety endpoints.

Frontline Forum Part 4: Solutions in the Management and Treatment of Basal Cell Carcinoma

Sandra Fyfe;Dermatology Times Staff;John Strasswimmer, MD, PhD;Andrew Weinstein, MD, FAAD;Neal Bhatia, MD;Laura Ferris, MD, PhD;Aaron Farberg, MD

May 30th 2023

In part 4 of this Frontline Forum series, John M. Strasswimmer, MD, PhD; Andrew H. Weinstein, MD; Neal Bhatia, MD; Laura Ferris, MD; and Aaron S. Farberg, MD, discuss solutions for managing and treating patients with basal cell carcinoma.

Frontline Forum Part 3: Solutions in the Management and Treatment of Basal Cell Carcinoma

Sandra Fyfe;Dermatology Times Staff;John Strasswimmer, MD, PhD;Andrew Weinstein, MD, FAAD;Neal Bhatia, MD;Laura Ferris, MD, PhD;Aaron Farberg, MD

May 23rd 2023

In part 3 of this Frontline Forum series, John M. Strasswimmer, MD, PhD; Andrew H. Weinstein, MD; Neal Bhatia, MD; Laura Ferris, MD; and Aaron S. Farberg, MD, discuss solutions for managing and treating patients with basal cell carcinoma.

Frontline Forum Part 2: Solutions in the Management and Treatment of Basal Cell Carcinoma

Sandra Fyfe;Dermatology Times Staff;John Strasswimmer, MD, PhD;Andrew Weinstein, MD, FAAD;Neal Bhatia, MD;Laura Ferris, MD, PhD;Aaron Farberg, MD

May 16th 2023

In part 2 of this Frontline Forum series, John M. Strasswimmer, MD, PhD; Andrew H. Weinstein, MD; Neal Bhatia, MD; Laura Ferris, MD; and Aaron S. Farberg, MD, discuss solutions for managing and treating patients with basal cell carcinoma.

Frontline Forum Part 1: Solutions in the Management and Treatment of Basal Cell Carcinoma

Sandra Fyfe;Dermatology Times Staff;John Strasswimmer, MD, PhD;Andrew Weinstein, MD, FAAD;Neal Bhatia, MD;Laura Ferris, MD, PhD;Aaron Farberg, MD

May 9th 2023

In part 1 of this Frontline Forum series, John M. Strasswimmer, MD, PhD; Andrew H. Weinstein, MD; Neal Bhatia, MD; Laura Ferris, MD; and Aaron S. Farberg, MD, discuss solutions for managing and treating patients with basal cell carcinoma.

Considerations in Treatment Selection for BCC

Laura Ferris, MD, PhD;Andrew Weinstein, MD, FAAD

April 7th 2023

Experts in dermatology comment on their considerations relating to treatment selection in their patients with basal cell carcinoma, highlighting the impact of cemipulab in this space.

Expert Perspectives on the Role of Interdisciplinary Care in BCC

Laura Ferris, MD, PhD;Andrew Weinstein, MD, FAAD

April 7th 2023

Laura Ferris, MD, PhD and Andrew Weinstein, MD, FAAD discuss the importance of multidisciplinary care in their patients with locally advanced basal cell carcinoma, reinforcing the role of the dermatologist in the care plan.